Product Overview
Berry Quotes Simulator (Quantification and Optimization of Trial Expectations Simulator) helps program development teams estimate the financial impact of trial design decisions. By simulating Phase 2 and Phase 3 trial outcomes, QUOTES calculates expected Net Present Value (eNPV) and Return on Investment (ROI), enabling innovative, data-driven strategy.
Forecast Financial Impact with Confidence: Get detailed projections for eNPV and ROI to quantify the financial impact of your clinical development strategy before trials begin.
Simulate Phase 2 & 3 Success: Model Phase 2 and Phase 3 outcomes to see how design choices affect trial success, timelines, and costs — and make smarter, data-driven decisions.
Deployment
- Web based
- Cloud Hosted
Pricing
- Subscription
- License Fee
More Information
How QUOTES Works
QUOTES enables data-driven financial forecasting for clinical development by modeling the financial impact of different trial strategies. Here’s how it works:
- Simulate Phase 2 Trials: Use tools like FACTS to simulate a range of Phase 2 trial designs, including variations in sample size, dose selection, and treatment populations.
- Model Phase 3 Outcomes: QUOTES uses Phase 2 results to predict Phase 3 outcomes, including trial success rates, costs, and timelines.
- Aggregate Results: Calculate key financial metrics such as Net Present Value (eNPV), Return on Investment (ROI), and overall trial performance for each design option.
- Compare Strategies: Evaluate and compare multiple strategies, including trial size, design, and go/no-go criteria, to identify the most profitable development approach.
By running thousands of simulations, QUOTES allows teams to visualize the financial trade-offs of different design choices. This approach makes it easier to justify trial decisions to stakeholders and ensure development plans are optimized for profitability and efficiency.
About the company
Berry Consultants (“Berry”) is a scientific consulting company specializing in innovative clinical trial design, Bayesian analysis, adaptive trial implementation, and software solutions for the pharmaceutical and medical device industry.
Berry was founded in 2000 by Donald Berry, PhD and his son, current President, Scott Berry, PhD. Since then, Berry has designed thousands of innovative adaptive trials for medical device, biotech, and pharmaceutical companies. In addition to Don and Scott, Berry currently employs full-time statistical and medical scientists to precisely tailor innovative flexible designs for each client.
